Fig. 1
From: Deciphering and advancing CAR T-cell therapy with single-cell sequencing technologies
The basics of CAR T-cells. (A) Illustration of the basic structure of the conventional TCR-CD3 complex and CAR molecule. (B) Flow scheme of the CAR T-cell manufacturing process. Autologous CAR T-cell manufacturing typically begins with leukapheresis of the patient. Then, the T cells are activated and amplified with antibody-coated beads. After that, the CAR construct is introduced into the T cells, typically by viral or non-viral vectors. Finally, CAR T-cells are expanded to the required amount and then infused into the patient after quality control testing